Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.26) per share. This is unchanged from the same period last year. The company reported quarterly sales of $4.25 million which beat the analyst consensus estimate of $3.72 million by 14.14 percent. This is a 6.60 percent decrease over sales of $4.55 million the same period last year.
CORRECTION: Vivos Therapeutics Q3 EPS $(0.26), Same YoY, Sales $4.25M Beat $3.72M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.26) per share. This is unchanged from the same period last year. The company reported quarterly sales of $4.25 million which beat the analyst consensus
Related Posts
TJX Companies Shares Gain On Solid Q2 Earnings Beat, Raised FY24 Guidance
TJX Companies Inc (NYSE: TJX) reported second-quarter FY24 sales growth of 8% year-on-year to $12.76 billion,
Midas Immersion Cooling To Supply 200 MW Of Immersion Cooling Equipment Solutions To Riot Platforms, Inc.
Agreement includes an initial purchase of 200 MW of immersion systems, with the option to supply up to 400 MW of additional immersion systems on the same terms. Initial sale brings total worldwide deployment of Midas
Dollar Tree, Dycom Industries, Chico’s FAS And Other Big Losers From Tuesday
U.S. stocks closed higher on Tuesday, with the Dow Jones gaining around 400 points. Here is the list of some big stocks recording losses in the previous session.